Patients
low-grade glioma, glial cell hyperplasia
TUMOR PROGRESSION
This retrospective study collected the clinical and imaging data of 41 patients with glial cell hyperplasia and 87 patients with low-grade glioma pathologically confirmed at the First Affiliated Hospital of Soochow University from March 2016 to March 2022. Both MRI plain and contrast-enhanced examination were performed on each patient. The inclusion criteria were: (1) Pathological data provided completely. (2) MRI plain and contrast-enhanced examination performed before surgical treatment. (3) No treatment given to interfere with tumor progression prior to examination. The exclusion criteria were: (1) Unqualified MRI scans. (2) Incomplete clinical data (Fig. 
Shows the inclusion and exclusion criteria for 41 patients with glial cell hyperplasia and 87 patients with low-grade glioma